Pediatric Vaccine Rollout
This carefully selected group of stocks represents companies positioned to benefit from the full FDA approval of COVID-19 vaccines for at-risk children. Our professional analysts have identified opportunities across the entire value chain, from vaccine manufacturers to healthcare providers and clinical research organizations.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Novavax, Inc.
NVAX
Current price
$9.58
A key competitor in the COVID-19 vaccine market; full approval for a rival product could increase the focus and potential market for all approved vacc...
A key competitor in the COVID-19 vaccine market; full approval for a rival product could increase the focus and potential market for all approved vaccine manufacturers.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
Moderna's pediatric vaccine approval is a significant catalyst that expands the market for children's immunization. This regulatory milestone not only benefits direct vaccine manufacturers but creates opportunities throughout the healthcare ecosystem, from research and development to administration and support services.
What You Need to Know
This group captures the full value chain affected by expanded pediatric vaccination, including mRNA technology developers, adjuvant providers, clinical research organizations, and specialized healthcare services. The FDA approval reduces risk in this market segment and signals potential long-term growth.
Why These Stocks
These companies were selected because they each play a vital role in the pediatric vaccine rollout. From direct beneficiaries like Moderna to competitors who may see increased interest, and from research organizations to healthcare providers, this collection represents both immediate opportunities and long-term growth potential.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+338.93%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 338.93% over the next year.
Stocks Rated Buy by Analysts
10 of 15 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
Breakthrough Science
The full FDA approval for Moderna's pediatric vaccine validates the entire mRNA technology platform, potentially accelerating adoption of similar innovations across multiple companies in this group.
Expanding Market Opportunity
With millions of at-risk children now eligible for fully approved vaccines, companies throughout the healthcare ecosystem stand to benefit from this newly unlocked market segment.
Public Health Priority
Government focus on protecting vulnerable populations creates a supportive environment for continued investment and innovation in pediatric vaccines and related healthcare services.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Uncle Sam's Semiconductor Stake
The U.S. government is considering an equity stake in Intel to boost domestic semiconductor manufacturing. This strategic move could create a ripple effect, benefiting other American companies involved in the chip-making industry.
The Cybersecurity Consolidation Wave
Accenture's record-breaking acquisition of CyberCX signals a major consolidation trend in the cybersecurity sector. This move highlights the growing demand for AI-powered security solutions, creating potential opportunities for other specialized cybersecurity firms to benefit from increased investment and M&A activity.
American Chipmakers: A Tariff-Driven Shift
President Trump has threatened to impose tariffs of up to 300% on semiconductors to boost domestic production. This creates a potential investment opportunity in U.S.-based semiconductor companies that stand to gain from a shift toward onshore manufacturing.
Frequently Asked Questions
Everything you need to know about the product and billing.